Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.
Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated an ability to target bone formation with a high degree of safety, suggesting it to be an attractive treatment modality vs. other bone growth factors and implanted devices.
Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.
Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated...
Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.
Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated an ability to target bone formation with a high degree of safety, suggesting it to be an attractive treatment modality vs. other bone growth factors and implanted devices.
Copy to clipboard 
